So tell me a little bit about that and what are some points that we can glean in terms of how we counsel patients.

Right.

So, you know, we-- with cystectomy, with prostatectomy, all this stuff, we've done plenty of patient-reported outcome data.

So the same has not necessarily been true for non-muscle invasive bladder cancer, and particularly when we have treatments that are new in this space.

It's never really been pioneered, right? So there's three studies that have been focused on UGN102, and in all of those studies, patient-reported outcome data was collected.

There's three different approved questionnaires that were collected for the-- there's a quality of life in MIBC, QLQ, in MIBC twenty-four, that's the name, I think.

And there's that one, and then there's our Core thirty, which is a general questionnaire, and one other one.

So what's on the horizon in this space? What other trials are we looking forward to to figure out what agents we might be able to add to this growing armamentarium of options?